Cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma.
Luciano J. Costa(University of Alabama at Birmingham), Parameswaran Hari(Medical College of Wisconsin), Carolyn C. Jackson(Centro de Investigación del Cáncer), Ravi Vij(Washington University in St. Louis), Shaji Kumar(Mayo Clinic), Ankit Kansagra(Southwestern Medical Center), Sundar Jagannath(Mount Sinai Hospital), Saurabh Chhabra(Medical College of Wisconsin), Natalie S. Callander(University of Wisconsin–Madison), Satish Valluri(Janssen (United States)), Jesús G. Berdeja(Tennessee Oncology), Arnob Banerjee(Johnson & Johnson (United States)), Thomas Martin(University of California, San Francisco), Jordan M. Schecter(Centro de Investigación del Cáncer), Yi Lin, Hong Tian(Massey University), Jennifer Marino(Janssen (United States)), Yubin Kang(Duke University)
Cited by 10
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k